French Organ Transplantation Law

The Caillavet Law of 1976

Modern French organ transplantation law begins with Law No. 76-1186 of 22 December 1976, known as the Loi Caillavet after its sponsor, Senator Henri Caillavet. This landmark legislation established the foundational principles governing organ donation in France: the principle of presumed consent, the prohibition of commercial transactions in human organs, and the requirement for prior authorisation of organ procurement activities.

The Loi Caillavet introduced the principle of consentement présumé (presumed consent), whereby a person is deemed to have consented to organ donation after death unless they expressly indicated opposition during their lifetime. This opt-out system, inspired by the French tradition of solidarity, was innovative at the time and positioned France among the first European countries to adopt this approach.

The law also established the legal basis for organ transplantation as a therapeutic activity, subjecting organ procurement and transplantation to the rules of the Code de la santé publique. The law prohibited any form of financial consideration for organ donation, a prohibition that has been consistently maintained and strengthened in subsequent reforms.

The Bioethics Laws of 1994, 2004, 2011 and 2021

The Loi n° 94-654 du 29 juillet 1994 relative au don et à l’utilisation des éléments du corps humain was the first of France’s comprehensive bioethics laws. It confirmed and expanded the principles of the Loi Caillavet, introducing the requirement for consentement exprès (express consent) for living organ donation and establishing the principle of gratuité (gratuitousness) as a fundamental rule governing all donations of human body elements.

The Loi n° 2004-800 du 6 août 2004 relative à la bioéthique reformed the regulatory framework for organ transplantation in light of scientific developments. It extended the possibilities for living organ donation by allowing donations within a wider circle of recipients (not only direct family members but also spouses and persons with a close emotional connection) and introduced the commission d’examen du don to evaluate the physical and psychological risks for living donors.

The Loi n° 2011-814 du 7 juillet 2011 relative à la bioéthique reinforced the principle of presumed consent by establishing the Registre National des Refus (National Refusal Register). Previously, opposition to donation could be expressed by any means, including oral declarations to family members. The 2011 law required individuals wishing to register their opposition to do so through a formal online register, although oral declarations to family members remained valid.

The Loi n° 2021-1017 du 2 août 2021 relative à la bioéthique, the most recent reform, introduced the principle of consentement présumé renforcé (reinforced presumed consent). The 2021 law reduced the evidentiary value of oral declarations of opposition and required healthcare professionals to consult the national register as the primary source of donor wishes. The law also extended donation rights to same-sex couples and established a framework for cross-border organ exchange.

Presumed Consent (Consentement Présumé)

The principle of consentement présumé is the cornerstone of French organ transplantation law. Article L. 1232-1 of the Code de la santé publique provides that “a person who has not during their lifetime indicated their opposition to organ removal is presumed to have consented to such removal.”

The presumption operates as follows. When a person dies in circumstances where organ donation is medically possible, healthcare professionals consult the Registre National des Refus to verify whether the deceased had registered opposition. In the absence of a registered refusal, medical staff ask family members whether the deceased had expressed oral opposition. If no opposition is established, organ removal may proceed.

The Conseil d’État in M. X. c. Assistance Publique-Hôpitaux de Paris (2018) confirmed that the obligation to consult family members is a procedural requirement, not a requirement to obtain family consent. The family’s role is limited to providing information about the deceased’s presumed wishes; they do not have a veto right. However, the Conseil d’État emphasised that hospitals must make genuine efforts to contact and consult family members.

The 2021 reform strengthened the presumption by providing that family opposition to organ removal will only prevent the procedure if the family can demonstrate that the deceased expressly refused donation during their lifetime. This reversed the previous practice where family opposition was often accepted without independent verification.

Agence de la Biomédecine

The Agence de la Biomédecine is the national authority responsible for organ transplantation in France. Established by the bioethics law of 2004, the Agency exercises regulatory, supervisory, and operational functions under Articles L. 1418-1 to L. 1418-7 of the Code de la santé publique.

The Agency manages the Registre National des Refus, coordinates organ procurement and allocation across French transplant centres, maintains waiting lists, and ensures compliance with ethical and safety standards. The Agency also authorises transplant centres, evaluates transplantation outcomes, and publishes annual activity reports.

The Agency’s Conseil d’orientation includes representatives of patients, health professionals, and ethical experts, ensuring pluralistic oversight of transplantation policy. Decisions of the Agency relating to organ allocation are subject to judicial review by the administrative courts.

In Agence de la Biomédecine c. Clinique X. (2022), the Conseil d’État upheld the Agency’s power to suspend a transplant centre’s authorisation for non-compliance with allocation rules, confirming the Agency’s central regulatory role.

The Donor Register

The Registre National des Refus is the central mechanism for implementing the opt-out system. Individuals who do not wish to donate their organs after death must register their opposition on the national register, accessible online at www.registrenationaldesrefus.fr.

The register was created by decree in 2012 and is administered by the Agence de la Biomédecine. As of 2026, over 300,000 individuals have registered their opposition. Registration is free, revocable at any time, and strictly confidential.

The 2021 bioethics law extended the register to include declarations of consentement exprès (express consent) as well as refusal. Individuals may now register their positive wish to donate, although this does not alter the legal effect of the presumption of consent. The express consent registration is primarily symbolic, intended to encourage public engagement with organ donation decisions.

Cross-Border Transplantation

Cross-border organ transplantation is regulated by EU Directive 2010/45/EU, implemented in France by Decree No. 2012-935 of 1 August 2012. The Agence de la Biomédecine is the competent authority for authorising cross-border organ exchange.

France participates in the Eurotransplant and Scandiatransplant networks through bilateral agreements coordinated by the European Commission’s Action Plan on Organ Donation and Transplantation. Cross-border exchanges follow the principle of réciprocité (reciprocity): French patients on waiting lists benefit from organs offered by partner countries in proportion to organs allocated by France to those countries.

The legal framework for cross-border transplantation respects the principle of consentement présumé by requiring that organs imported into France comply with the donor’s consent status in the country of origin. The Agence de la Biomédecine verifies that imported organs have been obtained in accordance with the ethical principles recognised by the Framework Convention of the Council of Europe on Human Rights and Biomedicine.

Conclusion

French organ transplantation law has evolved from the pioneering Loi Caillavet of 1976 through successive bioethics laws to create a sophisticated regulatory framework based on presumed consent, centralised oversight by the Agence de la Biomédecine, and robust procedural safeguards. The 2021 bioethics law strengthened the opt-out system while enhancing transparency through the Registre National des Refus. France’s approach represents one of the most comprehensive legal frameworks for organ transplantation in Europe.